Sign in Subscribe

Biological products industry

Antineoplastic agents

Revolutionary Approach to Anticancer Drug Sensitivity Prediction

Investigations at Genentech Inc. in South San Francisco, California, have led to the development of a groundbreaking computational procedure, REFINED, which significantly enhances predictive performance in anticancer drug sensitivity prediction tasks. This innovative methodology maps high-dimensional feature vectors into compact 2D images, enabling the application of convolutional neural networks (CNNs)

Antineoplastic agents

Revolutionary Approach to Anticancer Drug Sensitivity Prediction

Investigations at Genentech Inc. in South San Francisco, California, have led to the development of a groundbreaking computational procedure, REFINED, which significantly enhances predictive performance in anticancer drug sensitivity prediction tasks. This innovative methodology maps high-dimensional feature vectors into compact 2D images, enabling the application of convolutional neural networks (CNNs)

Antineoplastic agents

Revolutionary Approach to Anticancer Drug Sensitivity Prediction

Investigations at Genentech Inc. in South San Francisco, California, have led to the development of a groundbreaking computational procedure, REFINED, which significantly enhances predictive performance in anticancer drug sensitivity prediction tasks. This innovative methodology maps high-dimensional feature vectors into compact 2D images, enabling the application of convolutional neural networks (CNNs)

Biological products industry

Predictors of Discontinuing Injectable Cabotegravir/Rilpivirine and Virologic Outcomes After Resuming Oral Antiretroviral Therapy

Researchers at the University of California have conducted a retrospective cohort study to evaluate factors associated with discontinuation of long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) and describe virologic outcomes in those that returned to oral antiretroviral therapy (ART). The study found that individuals with substance use demonstrated a higher

Biological products industry

Lenacapavir Shows Promise in HIV Prevention with Equitable Access and Partnership

Gilead Sciences Inc. has been developing lenacapavir, a first-in-class HIV capsid inhibitor, for human immunodeficiency virus (HIV) prevention as pre-exposure prophylaxis (PrEP). The research concluded that lenacapavir holds potential for helping to end new HIV infections around the world. The company is committed to working with scientists, clinicians, communities, advocates,

Biological products industry

Owkin Launches K Pro, an Agentic AI Co-Pilot for Biopharma to Accelerate Drug Discovery and Development

K Pro, developed by Owkin, is a cutting-edge AI co-pilot that aims to revolutionize the biopharmaceutical industry by providing high-quality, clinically relevant answers to complex biological questions. This innovative platform leverages natural language interaction, integrating Owkin Zero, a fine-tuned biological large language model (LLM) that outperforms leading competitors. By unifying
See all